Mark Shackleton

Professor Director of Oncology

Alfred Health

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Collaborators (4)

Guillaume Lessene

Division Head

Walter and Eliza Hall Institute of Medical Research

Anthony M. Joshua

University Health Network

Gisela Mir Arnau

Vall d'Hebron Institute of Oncology

Rory Wolfe

MONASH UNIVERSITY

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mark Shackleton

Research Interests

Explore related searches

Contact this professor

Articles (13)

Collaborators (4)

Guillaume Lessene

Anthony M. Joshua

Gisela Mir Arnau

Rory Wolfe

Make your next move.

Mark Shackleton

Research Interests

Explore related searches

Contact this professor

Articles (13)

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 years

Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma

A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas

Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper

The role of surveillance imaging for resected high-risk melanoma

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review

Evaluation of Crizotinib Treatment in a Patient with Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi

Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

Collaborators (4)

Guillaume Lessene

Anthony M. Joshua

Gisela Mir Arnau

Rory Wolfe

Make your next move.